Management of Severe and Critical COVID-19 Infection with Immunotherapies

Early in the COVID-19 pandemic, clinicians and researchers sought to rapidly repurpose available candidate therapies for SARS-CoV-2 infection pending the development of directed antivirals and novel vaccines. Slowly, anecdotal case series and single-arm observational trials gave way to randomized control trials (RCTs) as the global research community mobilized to design, implement, and analyze studies in the midst of unprecedented pressure on healthcare systems. Despite early controversy surrounding the Emergency Use Authorization (EUA) and politicization of hydroxychloroquine therapy, progress soon followed in the form of remdesivir and dexamethasone, which became standard of care following EUA by the Food and Drug Administration (FDA) in May 2020(1) and release of the RECOVERY trial results in June 2020(2).

Source: Infectious Diseases Clinics of North America - July 18, 2022 Category: Infectious Diseases Authors: Janhavi Athale, Jolie Gallagher, Lindsay M. Busch Source Type: research